Effect of treatment by GNRH agonist on infertility in PCOD patients

The randomized, double -blinded clinical trial comparing gonadotropin – releasing hormone agonist injection effect before frozen embryo transfer versus placebo on improving the outcome of pregnancy in infertile patients with hyper androgenic polycystic ovary syndrome in the IVF/ICSI cycle

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140818018842N15

Enrollment

Registered

2018-10-24

Start date

2018-05-10

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hyper androgenic polycystic ovarian disease. Female infertility associated with anovulation

Interventions

Intervention 1: Intervention group: Receive depot preparation of the GNRH agonist (Luprolide acetate 3.75 mg) before frozen- thawed embryo transfer, one dose every 4 weeks, totally two doses. Interven

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Oligoovulation or anovulation. Clinical and/or biochemical signs of hyperandrogenism. Polycystic ovaries.

Exclusion criteria

Exclusion criteria: Patients with hyperanderogenism caused by hormonal drugs or other medications. Patients who have known sever organ dysfunction or mental illness. Pregnant women or being in Post- miscarriage period breastfeeding being in the 6 week postpartum period. Patients had congenital adrenal hyperplasia or were suspected of having Cushing s syndrome or an androgen – screening neoplasm.

Design outcomes

Primary

Measure	Time frame
Endometrium thickness. Timepoint: Before starting treatment and embryo transfer. Method of measurement: Trans vaginal ultrasonography.;The number of positive chemical pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: Laboratory test (BHCG over than 40 IU).;The number of successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Trans vaginal ultrasonography.	—

Measure

Time frame

Endometrium thickness. Timepoint: Before starting treatment and embryo transfer. Method of measurement: Trans vaginal ultrasonography.;The number of positive chemical pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: Laboratory test (BHCG over than 40 IU).;The number of successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Trans vaginal ultrasonography.

—

Secondary

Measure	Time frame
Live birth rate. Timepoint: At 28th week of pregnancy. Method of measurement: Trans abdominal ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Rashidi

Tehran University of Medical Sciences

asamaei@razi.tums.ac.ir+98 21 84901

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026